Risk-adapted treatment for childhood hepatoblastoma: Final report of the second study of the International Society of Paediatric Oncology - SIOPEL 2

European Journal of Cancer

Volumn 40, Issue 3, 2004, Pages 411-421

  Perilongo, G ^a   Shafford, E ^b   Maibach, R ^c   Aronson, D ^d   Brugieres L ^e   Brock, P ^f   Childs, M ^g   Czauderna, P ^h   MacKinlay, G ⁱ   Otte, J B ^j   Pritchard, J ^j,k   Rondelli, R ^l   Scopinaro, M ^m   Staalman, C ^d   Plaschkes, J ⁿ  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^b ROYAL LONDON HOSPITAL   (United Kingdom)

^c Swiss Institute for Applied Cancer Research   (Switzerland)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e INSTITUT GUSTAVE ROUSSY   (France)

^f Hospital for Sick Children   (United Kingdom)

^g UNIVERSITY OF LEICESTER   (United Kingdom)

^h MEDICAL UNIVERSITY OF GDANSK   (Poland)

ⁱ CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^j ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^k UNIVERSITY COLLEGE LONDON   (United Kingdom)

^l UNIVERSITY OF BOLOGNA   (Italy)

^m HOSPITAL DE PEDIATRÍA PROF DR JUAN P GARRAHAN   (Argentina)

ⁿ UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

more..

Author keywords

Chemotherapy; Children; Cisplatin; Hepatoblastoma; Prognostic factor

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN;

ABDOMINAL CANCER; ADOLESCENT; ARTICLE; BLOOD TOXICITY; BONE MARROW TOXICITY; CANCER MORTALITY; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CARDIOTOXICITY; CHILD; CHILDHOOD CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG FATALITY; FEMALE; HEPATOBLASTOMA; HUMAN; HUMAN TISSUE; INFANT; LIVER TRANSPLANTATION; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; POSTOPERATIVE CARE; PRIORITY JOURNAL; SIDE EFFECT; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 9144254451     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2003.06.003     Document Type: Article

References (21)

1. Brown J., Perilongo G., Shafford E.et al. Prognostic factors in childhood hepatoblastoma - results of the first prospective clinical trials of the International Society of Pediatric Oncology SIOPEL 1. Eur. J. Cancer. 2000:2000;1418-1425.
2. Pritchard J., Brown J., Shafford E.et al. Cisplatin, doxorubicin and delayed surgery for childhood hepatoblastoma. a successful approach - results of the first prospective study of the International Society of Paediatric Oncology J. Clin. Oncol. 18:2000;3819-3828.
3. Perilongo G., Brown J., Shafford E.et al. Hepatoblastoma presenting with lung metastases; treatment results of the first cooperative prospective study of the International Society of Paediatric Oncology on Childhood Liver Tumors. Cancer. 89:2000;1845-1853.
4. Douglass E.C., Green A.A., Wrenn E., Champion J., Shipp M., Pratt G.B. Effective Cisplatin (CDDP) based chemotherapy in the treatment of hepatoblastoma. Med. Pediatr. Oncol. 13:1985;187-190.
5. Ortega J.A., Douglass E.C., Feusner J.H.et al. Randomized comparison of cisplatin/vincristine/5-fluorouracil and cisplatin/continuous infusion doxorubicin for the treatment of paediatric hepatoblastoma (HB). a report from the Children's Cancer Group and the Paediatric Oncology Group J. Clin. Oncol. 18:2000;2665-2675.
6. Brugieres L., De Kraker J., Perel Y.et al. Pilot study of carboplatin-epirubicin in childhood hepatoblastoma. Proceedings of the SIOP Annual Conference. Med. Pediatr. Oncol. 23:1994;170. (abstr).
7. Dall'Igna P., Cecchetto G., Dominici C.et al. Carboplatin and doxorubicin (CARDOX) for non metastatic hepatoblastoma. a discouraging pilot study Med. Pediatr. Oncol. 36:2001;332-334.
8. Newell D.R., Pearson A.D.J., Balmanno K.et al. Carboplatin pharmacology in children the development of a paediatric dosing formula. J. Clin. Oncol. 19:1991;199-203.
9. Kaplan E., Meier P. Non parametric estimation from incomplete observations. J. Am. Stat. Assoc. 53:1958;457-481.
10. Kalbfleisch J., Prentice R. The Statistical Analysis of Failure Time Data. 1980;John Wiley and Sons, New York.
11. Brock P.R., Bellman S.C., Yeomans E., Pinkerton C.R., Pritchard J. Cisplatin ototoxicity in children; a practical grading system. Med. Pediatr. Oncol. 19:1991;295-300.
12. Douglass E.C., Finegold M., Reynolds M.et al. Cisplatin, vincristine and fluorouracil therapy for hepatoblastoma. a Paediatric Oncology Group Study J. Clin. Oncol. 11:1993;96-99.
13. Von Schweinitz D., Byrd D.J., Hecker H.et al. Efficiency and toxicity of ifosfamide, cisplatin and doxorubicin in the treatment of childhood hepatoblastoma. Eur. J. Cancer. 33:1997;1243-1249.
14. Black C.T., Cangir M., Choroszy D., Andassy R.J. Marked response to pre-operative high-dose cis-platinum in children with unresectable hepatoblastoma. J. Paed. Surg. 26:1991;1070-1173.
15. Katzenstein H.M., London W.B., Douglas E.et al. Treatment of unresectable and metastatic hepatoblastoma. a Pediatric Oncology Group Phase II study J. Clin. Oncol. 20:2002;3438-3444.
16. Von Schweinitz D., Hecker H., Schmidt-von Arndt G., Harms D. Prognostic factors and staging system in childhood hepatoblastoma. Int. J. Cancer. 74:1987;593-599.
17. Haas J.E., Feusner J.H., Finegold M.J. Small cell undifferentiated histology in hepatoblastoma may be unfavorable. Cancer. 15:2000;3130-3134.
18. Fuchs J., Rydzynski J., Von Schweinitz D.et al. Pretreatment prognostic factors and treatment results in children with hepatoblastoma. A report from the German Cooperative Pediatric Liver Tumour Study HB 94. Cancer. 95:2000;172-182.
19. Van Tornout J.M., Buckley J.D., Quinn J.J.et al. Timing and magnitude of decline of alpha-fetoprotein levels in treated children with unresectable or metastatic hepatoblastoma are predictors of outcome. a report from the Children's Cancer Group J. Clin. Oncol. 15:1997;1190-1197.
20. Exelby P.R., Filler R.M., Grosfeld Y.L. Liver tumors in children in particular reference to hepatoblastoma and hepatocellular carcinoma. American Academy of Paediatrics Surgical Section Survey - 1974. J. Paed. Surg. 10:1975;329-337.
21. Brock P.R., Koliouskas D.E., Barratt T.M., Yeomans E. Partial reversibility of cisplatin nephrotoxicity in children. J. Pediatr. 118:1994;530-534.